Public signal · 1-minute delayed

Signal brief

Source-backed market context you can read and share without an account.

CNTAVery BullishM&Anews

High materiality10/10

Eli Lilly to Acquire Centessa Pharmaceuticals for $6.3 Billion

Mar 31, 2026, 6:47 AM EDT3 sourcesAI-analyzed

Why it may matterVerify against the original reporting

The transaction offers a substantial cash premium over current trading prices, suggesting investor confidence and a strong potential for price appreciation. Historical examples show similar events often result in price increases towards bid price.

AI summary

What happened, with direct paths to the underlying reporting

Eli Lilly has announced it will acquire Centessa Pharmaceuticals for $38.00 per share, totaling approximately $6.3 billion. This acquisition includes contingent value rights tied to FDA approvals of Centessa's promising sleep disorder treatments, which could enhance Lilly's portfolio and revenue stream in the neuroscience sector.

Eli Lilly to acquire Centessa for $38 per share plus CVRs.
Acquisition expands Lilly's portfolio in sleep medicine.
Centessa's lead candidate, cleminorexton, shows promise in Phase 2a studies.
Deal includes contingent value rights related to FDA approvals.
Transaction expected to close in Q3 2026, pending approvals.

How to read this signal

Transparent limits for an AI-generated research aid

StockNews.AI groups source reporting, classifies the event, and measures subsequent price movement. This is informational research, not investment advice. Prices may be delayed or unavailable.

Eli Lilly to Acquire Centessa Pharmaceuticals for $6.3 Billion

Eli Lilly to acquire Centessa Pharmaceuticals in strategic deal